Epstein-Barr virus peptide-HLA complex (EBV pHLA)

The Epstein-Barr virus (EBV) peptide-HLA complex is a molecular assembly consisting of a viral peptide fragment bound to a human leukocyte antigen (HLA) molecule on the surface of an infected or malignant cell. This complex serves as the primary signal for the adaptive immune system, specifically CD8+ and CD4+ T cells, to recognize and eliminate EBV-infected cells through T-cell receptor (TCR) engagement. In the context of EBV-associated malignancies like post-transplant lymphoproliferative disorder (PTLD) and nasopharyngeal carcinoma, these complexes are critical therapeutic targets for adoptive T-cell therapies. Tabelecleucel (Ebvallo) is a prominent approved therapy that utilizes allogeneic EBV-specific T cells to target these complexes in an HLA-restricted manner. Beyond immune recognition, HLA class II molecules also function as entry receptors for EBV into B cells by interacting with the viral glycoprotein gp42. The virus often employs immune evasion strategies, such as downregulating HLA expression or using microRNAs to interfere with peptide processing, to reduce the density of these complexes on the cell surface. Therapeutic development focuses on identifying immunodominant peptides from latent proteins like LMP1, LMP2, and EBNA1 to create more potent TCR-T and vaccine interventions. These complexes are also implicated in the pathogenesis of autoimmune diseases, such as multiple sclerosis, where EBV infection may trigger cross-reactive immune responses against self-antigens.

Other names

EBV pMHC complexEpstein-Barr virus antigen-HLA complexEBV peptide-MHCPathogen-derived peptide-HLA complex from Epstein-Barr virus

Adoptive T-cell therapy involving T-cell receptor (TCR) recognition of specific viral peptides presented by HLA molecules, leading to the targeted lysis of EBV-infected or malignant cells.